Press Releases

Date Title and Summary View
Aug 02, 2007
Macrogenics Begins Global Phase 2/3 Protégé Study In Recent-onset Type 1 Diabetes Mellitus

Three Independent Clinical Trials Initiated with Teplizumab Manufactured at MacroGenics

Additional Formats
Jul 09, 2007
MacroGenics IND for West Nile Virus Monoclonal Antibody IS ACTIVE Phase 1 Clinical Trial to Commence in 2007
MacroGenics IND for West Nile Virus Monoclonal Antibody IS ACTIVE Phase 1 Clinical Trial to Commence in 2007 ROCKVILLE, MD.  July 9, 2007.  MacroGenics announced today that the companys investigational new drug (IND) application to the U.S. Food and Drug Administration for its monoclonal antibody
Additional Formats
Jan 03, 2007
MacroGenics and JDRF Form Partnership to Support Pivotal Phase II/III Clinical Trial of Anti-CD3 Monoclonal Antibody for Children and Adults with Recent-Onset Type 1 Diabetes

JDRF Provides MacroGenics with $2 Million in Funding for "Protégé" Trial

Additional Formats
Oct 16, 2006
MacroGenics Elects Industry Leader, Dr. John Maraganore, to Board of Directors
MacroGenics Elects Industry Leader, Dr. John Maraganore, to Board of Directors Rockville , Maryland.  October 16, 2006.   MacroGenics, Inc., a privately-held immunotherapeutics company, announced today that John Maraganore, Ph.D., President and CEO of Alnylam Pharmaceuticals, has joined the
Additional Formats
Oct 10, 2006
MacroGenics Receives Orphan Drug Designation from FDA for Monoclonal Antibody to Treat Type 1 Diabetes

Pivotal Trial of CD3 Monoclonal Antibody to Begin in 2006

Additional Formats
Oct 05, 2006
MacroGenics Novel Monoclonal Antibody Shows Potent Anti-tumor Activity against B-Cell Lymphoma in Preclinical Studies

Newly Published Data Validate CD32B as Key Target in Non-Hodgkins Lymphoma

Additional Formats
Oct 02, 2006
MacroGenics receives multiple government awards totaling more than $62 million to advance infectious disease programs
MacroGenics receives multiple government awards totaling more than $62 million to advance infectious disease programs Rockville , Maryland, October 2, 2006  MacroGenics, Inc. announced today that the National Institute for Allergy and Infectious Diseases (NIAID), part of the National Institutes of
Additional Formats
May 17, 2006
MacroGenics Raises $45M in Series C Financing - Company to Advance Monoclonal Antibody Clinical Programs
MacroGenics Raises $45M in Series C Financing - Company to Advance Monoclonal Antibody Clinical Programs Rockville, MD, May 17, 2006  MacroGenics, Inc., a privately-held biotechnology company developing therapeutics for autoimmune disorders, cancer, and infectious diseases, today announced that it
Additional Formats
Oct 19, 2005
MacroGenics Announces Grand Opening of New cGMP Manufacturing Facility in Montgomery County, Maryland Biotech Corridor
MacroGenics Announces Grand Opening of New cGMP Manufacturing Facility in Montgomery County, Maryland Biotech Corridor ROCKVILLE, MD.  October 19 th , 2005.  MacroGenics, Inc. today announced the grand opening of its recently completed cGMP manufacturing facility located in Rockville, Maryland.
Additional Formats
Jul 18, 2005
Promising Treatment for Juvenile Diabetes Advances with Agreement Signed by MacroGenics and Tolerance Therapeutics

Phase 2 Clinical Trial Set to Begin

Additional Formats
Jun 17, 2005
MacroGenics Builds Senior Management Team by Adding CFO and VP of Clinical Research
MacroGenics Builds Senior Management Team by Adding CFO and VP of Clinical Research ROCKVILLE, MARYLAND.  June 17, 2005  MacroGenics, Inc. today announced the addition of R. Nelson Campbell and Ronald L. Wilder, M.D., Ph.D. to the companys senior management team, as well as the promotions of Ezio
Additional Formats
Oct 19, 2004
MacroGenics Inc. To License Novel Monoclonal Antibody Target From OriGene Technologies, Inc.
MacroGenics Inc. To License Novel Monoclonal Antibody Target From OriGene Technologies, Inc. For Immediate Release Rockville, MD, October 19, 2004  ROCKVILLE, Md., OCTOBER 19 -- OriGene Technologies Inc. and MacroGenics, Inc. announced today that the companies have entered into a license agreement
Additional Formats
Oct 15, 2004
MacroGenics Completes Series B Financing
MacroGenics Completes Series B Financing For Immediate Release Rockville, MD, October 15, 2004  MacroGenics, Inc., a growing biotechnology company developing antibodies and vaccines to treat cancer, autoimmune disorders, and infectious diseases, announced the completion of its Series B financing of
Additional Formats
Apr 26, 2004
Neose Technologies and MacroGenics Sign Research Collaboration and License Agreement
CONTACTS: For Neose Technologies, Inc. Robert I. Kriebel - Sr. VP & CFO (215) 315-9000 Barbara Krauter - Manager (215) 315-9000 For MacroGenics Michael Richman - Exec. VP & CFO (301) 354-0681   For Immediate Release April 26, 2004 HORSHAM, Pa. , and ROCKVILLE , Md.
Additional Formats
Oct 29, 2003
Genzyme, MacroGenics Announce Joint Effort to Develop New Therapies for Immune-Mediated Diseases
CONTACTS: For Genzyme Sally Curley (investors) (617) 591-7140 Dan Quinn (media) (617) 591-5849 For MacroGenics Michael Richman (301) 354-0681   For Immediate Release October 29, 2003 CAMBRIDGE, Mass. and Rockville, Md . Genzyme Corp. (Nasdaq: GENZ) and MacroGenics, Inc.
Additional Formats
Sep 04, 2003
HHS Names UTMB, Seven Others as New Regional Centers To Focus on Biodefense Research
HHS Names UTMB, Seven Others as New Regional Centers To Focus on Biodefense Research The Department of Health and Human Services (HHS) today announced that the University of Texas Medical Branch at Galveston (UTMB) is among eight institutions nationwide receiving grants totaling approximately $350
Additional Formats
Jun 07, 2002
MacroGenics Acquires Eliance, Inc., and Establishes Partnership in Immunotherapeutics with UT Southwestern.

$12.6 Million in Financing Completed

Additional Formats
Apr 01, 2002
MacroGenics Announces Senior Appointments
MacroGenics Announces Senior Appointments Rockville, MD April 1, 2002 - MacroGenics, Inc., a biotechnology company that is developing immunotherapeutics for treating cancer and inflammatory diseases, announced two key appointments to the senior management team. Michael S.
Additional Formats
Sep 25, 2001
MacroGenics Raises $13.5 Million and Appoints President and CEO

Former MedImmune Senior Vice President joins MacroGenics; Company completes key license agreements and closure of second tranche of Series A financing, bringing total raised to $13.5MM.

Additional Formats